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Abstract
Introduction—Angiotensin receptor blockers (ARBs) are commonly used antihypertensive 
medication with several other additional proven benefits. Recent controversy on association of 
lung cancer and other solid malignancy with the use of ARBs is concerning, although the follow-
up studies have shown no such association.
Methods—We used data from the Department of Veterans Affairs electronic medical record 
system and registries to conduct a retrospective cohort study that compared first-time ARB users 
with nonusers in 1:15 ratio, after balancing for many baseline differences using inverse probability 
of treatment weights. We conducted time-to-event survival analyses on the weighted cohort.
Results—Of the 1 229 902 patients in the analytic cohort, 346 (0.44%) of the 78 075 treated 
individuals had a newly incident lung cancer and 6577 (0.57%) of 1 151 826 nontreated 
individuals were diagnosed with lung cancer. On double robust regression, the weighted hazard 
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ratio was 0.74 (0.67–0.83, P<0.0001), suggesting a lung cancer reduction effect with ARB use. 
There was no difference in rates by ARB subtype.
Conclusion—In this large nationwide cohort of United States Veterans, we found no evidence to 
support any concern of increased risk of lung cancer among new users of ARBs compared with 
nonusers. Our findings were consistent with a protective effect of ARBs.
Keywords
angiotensin receptor blockers; cancer registry; Department of Veterans Affairs; drug safety; 
inverse probability of treatment weight; lung cancer; propensity score; survival analysis
INTRODUCTION
Angiotensin receptor blockers (ARBs) are commonly prescribed for patients with 
hypertension: recently, there was a controversy regarding the utilization of ARBs and its 
association with an increased risk factor for lung cancer and other solid tumours [1,2]. Lung 
cancer is a major cause of morbidity with high fatality. The established risk factors for the 
development of lung cancer include smoking, environmental respiratory carcinogens and 
genetic factors.
The original report on the increased risk of lung cancer among ARB users originated in the 
form of a meta-analysis that used aggregate level clinical trial data [1,2]. The finding was 
subsequently refuted by additional meta-analyses, also using aggregate level data [2–4]. 
There were two individuallevel research studies [5,6], but they, instead of comparing ARB 
users vs. non-ARB users, compared ARB users with users of angiotensin-converting enzyme 
inhibitors (ACEi). In this case, as both the comparators are drugs that work similarly on the 
renin–angiotensin pathway, it may be speculated that the null association was probably 
secondary to common biological mechanisms. One study using individual-level data from 
the United Kingdom General Practice Research Database showed a statistical significant 
reduction of lung cancer among ARB users, when compared with ACEi users [6]. The 
Collaborative Transplant Study Report concluded an increased risk of respiratory tract 
cancer [7]. Hence, there is still some uncertainty on this topic; we used the electronic health 
record and cancer registry data from the United States Department of Veterans Affairs (VA), 
to evaluate whether Veterans receiving ARBs were at an increased risk of developing lung 
cancer compared with non-ARB users.
MATERIALS AND METHODS
Linked individual-level data on all eligible Veteran patients were obtained for fiscal years 
1999–2010 from VA data sources including the Central Cancer Registry (CCR), MedSAS, 
Decision Support System (DSS), Vital status file, health factors file [8] and the Corporate 
Data Warehouse (CDW) [9]. In this retrospective cohort study, we used the methods 
developed by Hernan et al. to evaluate whether ARB use was associated with an increased 
risk for lung cancer [10–12]. We generated a list of Veteran patients who received their first 
ARB dispensation at any time from 2003 to 2009, by querying two pharmacy data sources 
(DSS and CDW)from 1999 onwards. The goal was to identify for non-ARBs users and for 
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every ARB user in all the years from 2003 to 2009. To achieve this, we developed a 
calendar-year based staged random cohort selection method, starting with the year 2003 as 
follows; first, create a list of patients who were dispensed ARB treatment for the first time in 
the year 2003. Patients who filled their first ARB prescription without an outpatient clinician 
encounter within the prior 2 weeks’ time were excluded, as the probability of receiving an 
ARB prescription without a VA clinical encounter is very low and it might represent 
patients who were filling a non-VA prescription at a VA pharmacy. These 2003 ARB-
dispensed patients were now considered as ‘assigned to receive treatment’ (treated) in the 
year 2003. To identify their ‘assigned to receive no-treatment’ (not-treated) counterparts for 
the same year, we randomly identified patients in 1 : 15 ratio from the remaining pool of 
patients (those who had a VA outpatient clinician encounter in the year 2003 but were not 
dispensed any ARB from the VA pharmacy until the end of year 2003),with their start date 
of follow-up being a randomly selected date of the many dates of their respective VA 
outpatient clinical encounters in the year 2003.
We repeated this patient selection method for the years 2004–2009, with the exception that 
patients who were already selected into prior year cohorts were not eligible to be selected 
into subsequent year cohorts; this ensured statistical independence between cohorts. After 
completing this staged cohort selection process, we pooled all patients together creating the 
definitive cohort. Also not allowed to be a part of the selection process were patients
1. who if selected would have at baseline a diagnosis of cancer in the VA CCR 
(excluding nonmelanoma skin cancer);
2. who would not have established VA clinical, pharmacy and laboratory care at least 
6 months prior to date of treatment assignment;
3. with missing information of tobacco use in their VA health factor file; or
4. who would have been either less than 40 or more than 80 years of age (as the age 
group of 40–80 accounts for >98% of all lung cancer rates).
To account for the nonrandom treatment allocation, we computed propensity scores for the 
intention to start ARB treatment using a comprehensive set of baseline variables (Table 1). 
These baseline variables were derived from a look-back from 1999, using the most recent 
data for time-varying variables. To reduce statistical instability, patients in the not-treated 
group who had propensity scores beyond two standard deviations of the mean treated group 
propensity score were excluded [13]. We then weighted the cohort with the stabilized 
inverse probability of treatment weights (IPTWs) and created a weighted cohort. All patients 
were then followed until one of the following events: their last date of VA healthcare or 
related benefit; their death; date of diagnosis of lung cancer; or 31 December 2010 (a-priori 
determined end-point), whichever came first. All analyses were performed using SAS 9.2 
(SAS Institute, Cary, North Carolina, USA) using the SAS Grid environment. Data access 
and analysis was performed by the author G.R. The ability of IPTW to balance baseline 
covariates was assessed using standardized difference (Fig. 1). Incidence curves were drawn 
for both types of exposures and for the absolute difference between exposures (Fig. 2). To 
evaluate effect measures, we conducted double-robust regression [14] by fitting an IPTW-
weighted Cox-proportional hazard model with adjustments for selected variables, that is age, 
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race, Hispanic ethnicity, smoking status, BMI [weight (kg)/height (m2)] and diabetes 
mellitus after checking for proportionality assumption and reported respective hazard ratios 
with 95% confidence intervals. The advantages of double-robust regression have been 
previously reported [14].
In addition to our main analysis, we described the trends in utilization of ARBs in the VA. 
We also conducted two subanalyses; we first stratified by ARB subtypes to evaluate any 
possible individual drug effect on lung cancer risk. Because the rate of dispensation of 
telmisartan and olmesartan was together less than 0.25%, these two groups, being very 
small, were dropped: the ARB subtype analysis was restricted to candesartan, irbesartan, 
losartan and valsartan. Second, we stratified by smoking status, to evaluate the association 
between ARB use and lung cancer among three different stratums of smoking status.
This study was approved by the Institutional Review Board (IRB) of the Williams JB Dorn 
VA Medical Center and VA regulatory oversight organizations including the National Data 
Systems and the Patient Care Services. All data were stored and analysed using the 
resources of the Veterans Affairs Informatics and Computing Infrastructure (VINCI) by the 
author G.R.
RESULTS
The final cohort consisted of 1 228 960 unique patients. Baseline covariates with the greatest 
influence on the propensity to prescribe ARB were diabetes mellitus, serum creatinine level, 
concurrent or past use of ACEis, insulin use, BMI, congestive heart failure, chronic renal 
failure, thiazide diuretics, low-density lipoprotein levels and essential hypertension. Baseline 
comparisons between treated and not-treated groups, both with and without weighting, are 
reported in Table 1 and standardized differences between the two groups are shown in Fig. 
1. Because the untreated group was limited to those with propensity scores that were within 
two standard deviations of the treated group: the treated and not-treated appeared similar 
even before weighting with IPTW, improving statistical validity. The characteristics of the 
two groups represent patients likely to receive ARB and are not representative of the general 
VA patient population, explaining the high rate of hypertension (more than 96%) in all 
groups.
A total of 78 075 (6.4%) patients were classified as treated with a total follow-up time of 
350 878 person-years (mean 4.5±2.1 years) compared with 1 151 826 (93.7%) classified as 
not-treated with a total follow-up time of 5 098 085 person-years (mean 4.4±2.0 years). The 
number of lung cancers diagnosed in the treated and not-treated groups were 346 (0.44%) 
and 6577 (0.57%), respectively [relative risk (RR) 0.78 (0.70–0.86); P<0.001]. The 10-year 
number needed to treat (NNT) to reduce lung cancer incidence by one case is 329. The 
difference in incidence rates for lung cancer in the two groups is shown in Fig. 2. After 
double-robust regression, the adjusted hazard ratio for ARB was 0.74 (0.67–0.83, P<0.0001) 
(Table 2).
Smoking status at the start date of follow-up had the largest impact on the incidence of lung 
cancer with current smokers accounting for 5123 (0.9%), former smokers accounting for 
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1614 (0.4%) and never smoker accounting for 187 (0.1%). On subanalysis with recalculated 
IPTW within the different strata of smokers, the reduction in cancer incidence among 
current smokers persisted with a hazard ratio of 0.72 (0.64–0.82; P<0.001). Similar 
subanalysis among never-smokers and former smokers demonstrated an association in the 
same direction, but it did not reach statistical significance.
The number of patients who were censored, dead or lost-to-follow-up were similar between 
treated and not-treated groups at 67 615 (86.6%); 3981 (5.1%); 6133 (5.5%) vs. 979 036 
(85.0%); 61 365 (5.3%); and 104 848 (9.1%). The number of patients in the treated group 
who were on ARB treatment for at least 75% of their respective duration of follow-up was 
41 338 (53.0%); 27 121 (34.7%) were still on treatment at the end-of-follow-up. The number 
of patients who were on ARB for 25% or less of their respective duration of follow-up was 
19 405 (24.9%). The number of patients in the not-treated group who were subsequently 
started onARB was small at 70 735 (6.1%), with the mean time to initiation of ARB being 
2.9 years (±1.9).
Losartan [37 382 (48.7%)] was the most common ARB subtype prescribed in the VA 
followed by irbesartan [17 992 (23.4%)], valsartan [17 477 (22.8%)] and candesartan [3757 
(4.9%)]. There were temporal differences in the pattern of utilization of ARBs between 2003 
and 2009. Irbesartan accounted for more than 58% of ARB dispensations in the calendar 
year 2003 and 2004, but in the calendar years 2005 to 2009, losartan became the most 
common ARB accounting for 49.5, 66.4, 69.2, 70.2 and 73.6% of all ARBs across those 5 
years. Olmesartan and telmisartan had the lowest dispensation rates of 0.05 and 0.19%, 
respectively, with no observed lung cancers, and therefore were excluded from further ARB 
subtype subanalysis. Candesartan was preferentially dispensed to patients with cardiac 
arrhythmia or those prescribed beta-blockers, whereas valsartan was used preferentially 
among those with a diagnosis of heart failure. The preferred ARB type among patients with 
diabetes mellitus was losartan. The crude rates of lung cancer were highest for candesartan 
and irbesartan, but this was not found in the time-to-event survival analysis model adjusted 
for smoking status, BMI, diabetes mellitus, race, ethnicity and age, in which no ARB 
subtype was found to be significantly different than losartan in relation to lung cancer (Table 
3).
DISCUSSION
We used retrospective data from the nationwide cohort of United States Veterans, to 
evaluate the impact of real-world use of ARBs on the long-term risks for the development of 
lung cancer. Our analysis included a total cohort of more than one million individual 
patients with over five million combined person-years of follow-up, potentially the largest 
long-term medication safety research study. We found that intention to dispense ARBs was 
not associated with an increased risk of lung cancer. On the contrary, it appeared to have a 
protective effect [hazard ratio 0.74 (0.67–0.83, P<0.0001)], with a small absolute risk 
reduction of 0.30 lung cancers per 1000 person-years in the ARB-treated group. As shown 
in weighted incidence curves (Fig. 2), the difference in risk among ARB-prescribed and 
nonprescribed group starts to emerge after the third year and consistently increases over the 
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consequent years. On stratified analysis, the protective effect was statistically significant 
only among those who at the start of follow-up were current smokers.
Our study findings are in contrast with those reported by Sipahi et al. [1], who reported a 
modest increase in risk. The meta-analyses showed that exposure to maximal daily doses of 
ARBs for at least 3 years increased lung cancer, but the excess risk does not become 
apparent at lower levels of total exposure. Although we were unable to include dose 
information in our analysis – due to data unavailability – it is most likely that lower drug 
doses are prescribed in the real world (especially in an elderly VA cohort). Further, the 
cancer protective effect appeared to be more prominent around the thirrd year after start of 
treatment. Our subanalysis did not reveal any ARB subtype effect, but this cannot be ruled 
out, as the use of telmisartan, the most prevalent ARB subtype in the study from Sipahi et al. 
[1], was almost negligible in the VA.
The Collaborative Transplant Study concluded that among kidney transplant recipients, 
ACEi/ARB treatment was associated with a significant increase in the rate of respiratory/ 
intrathoracic tumours in the subpopulation of patients with a history of smoking [7]. In 
contrast, we found that smokers on ARB (dominantly losartan) were in fact associated with 
a lower risk of lung cancer than nonsmokers on ARB.
To our knowledge, this is the first United States Veteran population-based study that 
evaluated the relationship between ARBs dispensation and lung cancer, the first to use 
individual-level linked claims, electronic medical records and cancer registry data inside the 
new VINCI environment. Such large studies that evaluate safety concerns are few. Recently, 
a Danish nationwide cohort study used predominant administrative claims data to show no 
significant cancer risk increase among new ARB users compared with new ACEi users 
[adjusted rate ratio, 0.99; 95% confidence interval (CI) 0.95–1.03] and, specifically, no 
significant difference in lung cancer risk (adjusted rate ratio, 0.92; 95% CI 0.82–1.02) [5]. 
Similar to our findings, a study based on Taiwan National Health Insurance Database 
reported an independent association of ARB use with a decreased risk for cancer occurrence 
among patients with systemic hypertension (hazard ratio 0.66, 95% CI 0.63–0.68, P<0.001) 
[15]. Such beneficial results might be worth investigating, especially as any efficient 
cardiovascular therapy might prolong life and thereby expose the patient to an increased risk 
of cancer of all forms [16].
We believe that this study is the largest to date to investigate the relationship between ARB 
exposure and lung cancer risk. More epidemiological and clinical data are accumulating in 
this area and this investigation is timely, especially considering the recent meta-analysis 
carried out by Sipahi et al. [1]. With observational data, one can never be sure that a model 
for the treatment assignment mechanism (IPTW-weighted Cox-proportional hazard model) 
or a model for the counterfactual data is correct, so to partly overcome this limitation, we 
conducted a double-robust regression. In such a model, the resulting estimator is double-
robust when either a model for the treatment assignment mechanism or a model for the 
distribution of the counterfactual data is correctly specified, giving the investigators two 
opportunities for bias control [14], and improving on previous approaches. Another strength 
aspect of the design is using IPTW on the basis of propensity score to balance the two 
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comparative groups allowed us to control for measured confounders and to approximate 
randomized trial designs.
Nevertheless, although one can measure certain confounders, many can never be measured. 
This is especially an important limitation, as some of these confounders may rise due to 
medical activities that are not captured in the VA medical records: for instance, some 
patients who were classified as not-receiving ARB might have received ARBs outside the 
VA. However, this specific effect is probably minimal, as lower copay and governmental 
benefits administered by the VA pharmacy are strong incentives for Veterans to dispense 
their ARBs consistently via VA pharmacy. Although it is reasonable to expect that the 
treated and not-treated groups in this observational study are balanced on the variables used 
to generate the propensity scores, unlike a true-randomized experiment, the IPTW procedure 
will not balance unmeasured confounding such as latent or undiagnosed disease or disease 
severity. Thus, the bias from lack of information on unmeasured confounding variables 
cannot be excluded. However, most of the established confounders such as diabetes mellitus, 
age and smoking are measured in our study, and have been used in the computation of 
propensity scores; thus, the bias from major confounders is less likely. In addition, we have 
incorporated variables that may approximate instrumental variables (such as serum 
creatinine) that are expected to be related to ARB dispensation but unrelated (or very weakly 
related) to outcome; instrumental variables when balanced using propensity scores are 
thought to balance unmeasured confounders.
Other limitations are that nonadherence to the dispensed drugs might bias results towards the 
null, especially if ARBs were associated with lung cancer; however, a bias to the null would 
not explain the observed protective effect, which is away from the null. Also, by comparing 
treated to not-treated, a surveillance bias for lung cancer might have been created because 
patients under antihypertensive treatment are more likely to have opportunities to report 
symptoms of lung cancer to their physicians. However, this surveillance bias is also 
expected to reduce the effect measure towards one or the null and thus reduce the probability 
of detecting a reduced risk of lung cancer. Also, as this is an intention-to-treat analysis, 
cross-contamination between the two groups may bias the results. To investigate the risk of 
cross-contamination, we examined our data and found that only 6.1% of the not-treated 
group was prescribed ARBs after enrolment (started ARBs during interval follow-up); this 
crossover is also likely to move our findings towards the null, if ARBs are indeed protective. 
The observed rate of lung cancer for each age group may appear to be lower than the 
expected rate for a comparable US general population. This may be explained by 
nondifferential bias from incomplete reporting within a hospital-based cancer registry or the 
use of cancer as a baseline exclusion criterion. Finally, we are aware that our average 
follow-up time of 4.5 years may not fully account for the possible causal biological effect of 
ARB intake on cancer occurrence, but in this follow-up period, no increased risk was 
observed.
In conclusion, in this large nationwide cohort of United States Veterans, we found no 
evidence to support a concern of increased risk of lung cancer among those dispensed ARB 
(predominantly losartan) compared with those not dispensed by presenting evidence of a 
protective relationship. These findings are considered additional reassurance to the Foods 
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and Drug Administration conclusion that ARBs are at least not harmful for lung cancer 
incidence. Also, such findings are useful to stimulate further research on the subject, if 
indeed ARBs had any protective association.
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Balance achieved for selected covariates. Only selected variables reported. Black vertical 
line represents standardized difference of 10. Postweighting, all variables had a standardized 
difference of less than 10. ACEi, angiotensin-converting enzyme inhibitors; CCB, calcium 
channel blockers; CHF, congestive heart failure; CRF, chronic renal failure; HDL, high-
density lipoprotein; HTN, essential hypertension; LDL, low-density lipoprotein; race (AA), 
African–American; race (Haw or PI), race Hawaiian or Pacific Islander; race (mixed other), 
mixed other race; race (others), other race; race (W and AA), both white and AA.
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Weighted incidence curve for lung cancer. HR, hazard ratio.
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TABLE 1
Baseline covariates, before and after weighting with inverse probability of treatment weights
Treated vs. untreated (not-weighted)
76 797 vs. 1 151 955
Treated vs. untreated (weighted)
78 075 vs. 1 151 826
Demographics
  Age 63.2 ± (9.3) vs. 62.9 ± (9.7) 62.9 ± (9.6) vs. 63 ± (9.7)
  Male 73 101 (95.2%) vs. 1098,944 (95.4%) 74 957 (96%) vs. 1 098 716 (95.4%)
  Race
    White 60 293 (78.5%) vs. 918 584 (79.7%) 62 675 (80.3%) vs. 917 671 (79.7%)
    African-American 12 829 (16.7%) vs. 182 836 (15.9%) 12 026 (15.4%) vs. 183 360 (15.9%)
    Mix of white and African-American race 1072 (1.4%) vs. 15 744 (1.4%) 1031 (1.3%) vs. 15 759 (1.4%)
    Mixed other races 1399 (1.8%) vs. 20 722 (1.8%) 1427 (1.8%) vs. 20 730 (1.8%)
    Other races 1204 (1.6%) vs. 14 069 (1.2%) 918 (1.2%) vs. 14 307 (1.2%)
  Hispanic ethnicity 4227 (5.5%) vs. 60 932 (5.3%) 3939 (5%) vs. 61 062 (5.3%)
  VA and Medicare dual beneficiary 40 514 (52.8%) vs. 586 712 (50.9%) 40 166 (51.4%) vs. 588 007 (51%)
  Religion
    Catholic 19 440 (25.3%) vs. 287 057 (24.9%) 19 274 (24.7%) vs. 287 296 (24.9%)
    Protestant 47 214 (61.5%) vs. 714 086 (62%) 48 537 (62.2%) vs. 713 645 (62%)
    Jewish 1295 (1.7%) vs. 16 903 (1.5%) 1141 (1.5%) vs. 17 057 (1.5%)
    Other 8848 (11.5%) vs. 133 909 (11.6%) 9123 (11.7%) vs. 133 828 (11.6%)
  Smoking status
    Current 36 362 (47.3%) vs. 565 050 (49.1%) 39 354 (50.4%) vs. 563 814 (48.9%)
    Former 29 604 (38.5%) vs. 428 186 (37.2%) 28 361 (36.3%) vs. 429 107 (37.3%)
    Never 10 831 (14.1%) vs. 158 719 (13.8%) 10 361 (13.3%) vs. 158 906 (13.8%)
  Substance abuse
    Alcohol 8746 (11.4%) vs. 143 521 (12.5%) 10 694 (13.7%) vs. 142 784 (12.4%)
    Substance 6153 (8%) vs. 99 368 (8.6%) 7467 (9.6%) vs. 98 955 (8.6%)
  BMI 31.3 ± (5.9) vs. 30.2 ± (5.6) 30.2 ± (5.5) vs. 30.3 ± (5.7)
Comorbidity
  Diabetes mellitus 26 552 (34.6%) vs. 264 426 (23%) 18 708 (24%) vs. 272 706 (23.7%)
  Essential hypertension 74 228 (96.7%) vs. 1 131 618 (98.2%) 76 167 (97.6%) vs. 1 130 276 (98.1%)
  Myocardial infarction 1465 (1.9%) vs. 15 480 (1.3%) 1041 (1.3%) vs. 15 875 (1.4%)
  Cardiac dysrhythmia 13 008 (16.9%) vs. 178 070 (15.5%) 11 778 (15.1%) vs. 179 102 (15.5%)
  Congestive heart failure 7008 (9.1%) vs. 56 598 (4.9%) 4051 (5.2%) vs. 59 582 (5.2%)
  Acute cerebrovascular disease 3506 (4.6%) vs. 48 065 (4.2%) 3507 (4.5%) vs. 48 347 (4.2%)
  Chronic obstructive pulmonary disease 15 992 (20.8%) vs. 232 758 (20.2%) 15 409 (19.7%) vs. 233 146 (20.2%)
  Asthma 5130 (6.7%) vs. 69 702 (6.1%) 4444 (5.7%) vs. 70 119 (6.1%)
  Chronic renal failure 4920 (6.4%) vs. 32 282 (2.8%) 2224 (2.8%) vs. 34 785 (3%)
  Ulcerative colitis 646 (0.8%) vs. 10 275 (0.9%) 692 (0.9%) vs. 10 238 (0.9%)
  Rheumatoid arthritis 1620 (2.1%) vs. 25 514 (2.2%) 1626 (2.1%) vs. 25 430 (2.2%)
  Osteoarthritis 24 427 (31.8%) vs. 380 447 (33%) 25 612 (32.8%) vs. 379 532 (33%)
  Benign prostatic hyperplasia 15 197 (19.8%) vs. 239 548 (20.8%) 15 728 (20.1%) vs. 238 792 (20.7%)
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Treated vs. untreated (not-weighted)
76 797 vs. 1 151 955
Treated vs. untreated (weighted)
78 075 vs. 1 151 826
  HIV 277 (0.4%) vs. 4530 (0.4%) 337 (0.4%) vs. 4508 (0.4%)
  Hepatitis B 1434 (1.9%) vs. 21 442 (1.9%) 1478 (1.9%) vs. 21 445 (1.9%)
  Hepatitis C 3849 (5%) vs. 59 212 (5.1%) 4126 (5.3%) vs. 59 112 (5.1%)
  Mood disorder 21 642 (28.2%) vs. 324 517 (28.2%) 22 173 (28.4%) vs. 324 474 (28.2%)
  Schizophrenia 2931 (3.8%) vs. 47 188 (4.1%) 3809 (4.9%) vs. 47 013 (4.1%)
  Personality disorder 1848 (2.4%) vs. 29 417 (2.6%) 2258 (2.9%) vs. 29 320 (2.5%)
  Epilepsy 1823 (2.4%) vs. 29 632 (2.6%) 2189 (2.8%) vs. 29 496 (2.6%)
  History of coma 317 (0.4%) vs. 4485 (0.4%) 313 (0.4%) vs. 4502 (0.4%)
  History of suicidality 512 (0.7%) vs. 8314 (0.7%) 630 (0.8%) vs. 8276 (0.7%)
Concomitant medications
  Angiotensin-converting enzyme inhibitors 54 211 (70.6%) vs. 564 332 (49%) 38 380 (49.2%) vs. 579 712 (50.3%)
  Antidepressants 12 668 (16.5%) vs. 182 006 (15.8%) 12 115 (15.5%) vs. 182 448 (15.8%)
  Betablockers 22 123 (28.8%) vs. 296 580 (25.7%) 18 713 (24%) vs. 298 609 (25.9%)
  Calcium channel blocker 9946 (13%) vs. 122 186 (10.6%) 7544 (9.7%) vs. 123 722 (10.7%)
  Glucocorticoids 2820 (3.7%) vs. 37 399 (3.2%) 2283 (2.9%) vs. 37 673 (3.3%)
  Insulin 8685 (11.3%) vs. 59 044 (5.1%) 4211 (5.4%) vs. 63 384 (5.5%)
  Statins 5405 (7%) vs. 68 124 (5.9%) 4294 (5.5%) vs. 68 890 (6%)
  5-alpha-reductase inhibitor 1658 (2.2%) vs. 24 412 (2.1%) 1596 (2%) vs. 24 437 (2.1%)
  Thiazide diuretics 25 926 (33.8%) vs. 326 393 (28.3%) 20 921 (26.8%) vs. 330 064 (28.7%)
Baseline laboratory
  Alanine aminotransferase 33.5 ± (19.6) vs. 33.3 ± (19.9) 33 3 ± (18.6) vs 33.3 ± (20.1)
  Asparatate aminotransferase 28.5 ± (16.9) vs. 28.8 ± (16.2) 29 ± (18.4) vs. 28.7 ± (16.2)
  International normalized ratio 1.4 ± (0.5) vs. 1.4 ± (0.5) 1.4 ± (0.4) vs. 1.4 ± (0.5)
  Platelet count 158.5 ± (33.5) vs. 157.4 ± (31.7) 157 ± (30) vs. 157.5 ± (31.9)
  Albumin 4.1 ± (0.4) vs. 4.1 ± (0.3) 4.1 ± (0.4) vs. 4.1 ± (0.3)
  High-density lipoprotein 43.2 ± (7.6) vs. 43.7 ± (7.5) 43.8 ± (7.7) vs. 43.7 ± (7.5)
  Hemoglobin 14.4 ± (1.4) vs. 14.5 ± (1.2) 14.5 ± (1.3) vs. 14.5 ± (1.2)
  Low-density lipoprotein 105 ± (30.3) vs. 107.9 ± (28.5) 107.8 ± (30.2) vs. 107.8 ± (28.5)
  Potassium 4.3 ± (0.5) vs. 4.3 ± (0.4) 4.3 ± (0.4) vs. 4.3 ± (0.4)
  Creatinine 1.2 ± (0.5) vs. 1.1 ± (0.4) 1.1 ± (0.3) vs. 1.1 ± (0.4)
  Total cholesterol 176.9 ± (39.4) vs. 178.6 ± (37) 178 ± (38.4) vs. 178.5 ± (37.2)
  Trigylcerides 164.1 ± (90.8) vs. 158.6 ± (85.2) 158.4 ± (86.5) vs. 158.9 ± (85.5)













Rao et al. Page 14
TABLE 2
Adjusted hazard ratio by double-robust regression
Variables Hazard ratio
Angiotensin receptor blocker 0.74 (0.67–0.83, P < 0.0001)
Age group (Reference ’≥70’)
  65–70 years 1.05 (0.99–1.13, P = 0.1191)
  60–65 1.00 (0.94–1.07, P = 0.9025)
  55–60 0.58 (0.54–0.62, P < 0.0001)
  50–55 0.39 (0.35–0.43, P < 0.0001)
  45–50 0.20 (0.16–0.24, P < 0.0001)
  40–45 0.07 (0.04–0.11, P < 0.0001)
Race (reference ’white’)
  African-American 1.19 (1.11–1.27, P < 0.0001)
  Mix of white and 1.21 (0.99–1.46, P = 0.059)
    African-American race
  Mixed other races 0.50 (0.36–0.7, P < 0.0001)
  Other races 1.74 (1.51–2, P < 0.0001)
Hispanic ethnicity 0.45 (0.38–0.53, P < 0.0001)
Smoker (reference ’Never’)
  Current 6.54 (5.65–7.57, P < 0.0001)
  Former 2.84 (2.44–3.31, P < 0.0001)
BMI 0.92 (0.91–0.92, P < 0.0001)
Diabetes mellitus 1.02 (0.96–1.08, P = 0.5557)
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TABLE 3
Subanalysis among treated for the relationship between angiotensin receptor blocker subtype and lung cancer 
incidence
Stratified by smoking statusa HR for ARB (95% CI) P
  All current smokers 0.72 (0.64–0.82) <0.001
  All former smokers 0.86 (0.70–1.07) 0.175
  All never smoked 0.42 (0.18–1.02) 0.06
Stratified ARB subtype in a cohort of all ARB usersb HR for ARB subtype (95% CI) P
  Losartan 1 (reference)
  Candesartan 1.00 (0.67–1.51) 0.79
  Irbesartan 0.94 (0.73–1.22) 0.95
  Valsartan 0.94 (0.69–1.27) 0.99
ARB, angiotensin receptor blocker; CI, confidence interval; HR, hazard ratio.
a
Adjusted for age, race, Hispanic ethnicity, diabetes mellitus and BMI.
b
Adjusted for age, race, Hispanic ethnicity, smoking status, diabetes mellitus and BMI for all patients.
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